• Test Code:
    4820
  • Department:
  • Test Synonyms:
    RNA ExomeTranscriptome
  • CPT Code(s):
    81455
Background:

This test is designed to sequence mRNA from solid tumors for transcriptome analyses. The resulting data are used to screen for fusion genes and to assess the expression of gene variants/mutations (for correlation with tumor DNA sequencing results).  The data may also be used for pathway analyses and other analytics, but such analyses are not included in the clinical report. 

Reasons for Referral:  Advanced stage solid tumor.

Methodology:

The tumor is examined microscopically and tumor-rich areas are identified for dissection and RNA extraction. Ideally, the submitted material should contain 50% or more tumor fraction.  After purification and quantitation, the RNA is converted to cDNA and sequenced using an Illumina RNA Exome kit run on an Illumina next generation sequencing platform. 

Specimen Requirements:

  • A paraffin block, or 
  • 10 unstained sections of tumor (4-5 microns)(15 sections for small biopsies).Contact
  • Client Services for shipping materials and procedures at (855) 535-1522.

Test Performed (Days):

Weekly

Turn Around Time:

21-28 days

Shipment Sensitivity Requirements:

  • Keep specimen cool during transit, but do not ship on dry ice.
  • Please use the cold pack provided in the KDL shipping kit.
  • Ship the specimen overnight express, using the FedEx priority overnight label provided.  
  • Contact Client Services for shipping materials and procedures at (855) 535-1522.
 

References:

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More